Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
05/2003
05/21/2003EP1311694A1 Pyruvate:nadp+ oxidoreductase and uses thereof
05/21/2003EP1311692A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
05/21/2003EP1311680A2 Nucleic acid molecules encoding plant cell cycle proteins and uses therefor
05/21/2003EP1311679A2 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
05/21/2003EP1311677A2 Regulation of human p2y1-like g protein-coupled receptor
05/21/2003EP1311674A2 Compositions and methods for the diagnosis and treatment of tumor
05/21/2003EP1311673A2 Compositions and methods for the therapy and diagnosis of prostate cancer
05/21/2003EP1311668A2 Compositions and methods for the diagnosis and treatment of tumor
05/21/2003EP1311666A2 Progression suppressed gene 13 (psgen 13) and uses thereof
05/21/2003EP1311665A2 Kidney-specific protein
05/21/2003EP1311664A2 Microtubule-associated proteins and tubulins
05/21/2003EP1311663A2 Claudin polypeptides
05/21/2003EP1311662A2 Compositions and methods for the diagnosis and treatment of tumor
05/21/2003EP1311549A2 Composition for the elimination of autoreactive b-cells
05/21/2003EP1311547A2 Diagnosis and treatment of cardiovascular conditions
05/21/2003EP1311539A2 Pro-apoptotic fragments of the dengue virus envelope glycoproteins
05/21/2003EP1311537A2 Identification of a cam-kinase ii inhibitor
05/21/2003EP1311536A2 Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies
05/21/2003EP1311530A2 Production of humanized antibodies in transgenic animals
05/21/2003EP1311529A1 Novel tumor suppressor encoding nucleic acid, ptx1, and methods of use thereof
05/21/2003EP1311297A1 A method for reducing stress-induced overproduction of neuropeptide y in an individual
05/21/2003EP1311290A2 Expression of herstatin, an alternative her-2/neu product, in cells that express either p185her-2 or the egf receptor inhibits receptor activity and cell growth
05/21/2003EP1311282A1 High affinity integrin polypeptides and uses thereof
05/21/2003EP1015593B1 Hepatitis b virus polypeptides
05/21/2003EP0837699B1 Immunovectors for the intracellular and intranuclear transport
05/21/2003EP0633931B1 Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
05/21/2003EP0573551B1 Serine-rich peptide linkers
05/21/2003EP0411031B1 THE HUMAN C3b/C4b RECEPTOR (CR1)
05/21/2003CN1419597A Simultaneous stimulation and concentration of cells
05/21/2003CN1419566A A method of production of LgG
05/21/2003CN1109041C Process for preparing substituted disulfide derivative and targeted form thereof
05/21/2003CN1108818C Activated immune globulin
05/20/2003US6566505 Antibodies to Mch6 polypeptides
05/20/2003US6566504 Adding to the protein solution a cyclodextrin in an amount sufficient to form a stable complex with the protein, lyophilizing, recovering lyophilized protein/cyclodextrin complex, heating complex to inactivate viruses
05/20/2003US6566498 Proteins for use in the treatment of thrombosis and tumor metastisis
05/20/2003US6566492 Synthetic peptides of type II collagen for cartilage resorption assays
05/20/2003US6566328 Administering to the patient a therapeutically effective amount of a polypeptide for therapy of patient in need of agonist effect of human growth hormone
05/20/2003US6566325 And isolated nucleic acids containing coding regions of genes encoding such proteins; for use in gene therapy treatment of cancer, autoimmune diseases, viral diseases
05/20/2003US6566117 Immortal cell line derived from grouper Epinephelus coioides and its applications therein
05/20/2003US6566095 Blocking transmission of viral particles to animals; obtain animal, administer antibody, incubate with viral sample, monitor viral infection, reduction in viral infection indicates antagonist
05/20/2003US6566092 Nucleotide sequences coding polypeptide for use in the treatment nervous system disorders
05/20/2003US6566091 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders
05/20/2003US6566087 Detection of preferential enzymatic polypeptide; obtain sample containing enzymatic polypeptide, expose to modulator, monitor binding, detect adjustment in enzyme activity
05/20/2003US6566085 Synthetic peptides, antibodies directed against them, and the use thereof
05/20/2003US6566084 Detecting hydrolysis of cocaine compound; obtain cocaine mixture, incubate with antibody, monitor generation of benzoic zacid
05/20/2003US6566082 T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions
05/20/2003US6566077 Qualitative or quantitative analysis of immunoglobulin; generate solid support, incubate with immunoglobulin mixture, wash microtiter plate, detect complexed immunoglobulin
05/20/2003US6566076 Detection and diagnosis of conditions associated with lung injury
05/20/2003US6566066 Aquaporin-8 variant
05/20/2003US6566054 Cyclin dependent kinase mutants, and diagnostic and therapeutic uses related thereto
05/20/2003US6566048 Acetyl-COA-carboxylase from Candida albicans
05/20/2003US6565857 Coding human leukocyte antigen; anticancer, antitumor agent
05/20/2003US6565856 Polypeptide; inducting immunology response
05/20/2003US6565855 Polypeptides; genetic engineering
05/20/2003US6565849 Methods of enhancing activity of vaccines and vaccine compositions
05/20/2003US6565848 Cadherin-like asymmetry protein-1, and methods for its use
05/20/2003US6565843 Protein-induced tissue morphogenesis
05/20/2003US6565827 Anticarcinogenic agents
05/20/2003CA2075695C Monoclonal antibodies to sulfonated polymers
05/15/2003WO2003040725A2 Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen
05/15/2003WO2003040394A2 Production of recombinant proteins in vivo and use for generating antibodies
05/15/2003WO2003040384A1 Recombinant antibodies for the detection and neutralization of anthrax toxin
05/15/2003WO2003040374A1 METHODS AND COMPOSITIONS FOR ENHANCED PROTEIN EXPRESSION AND/OR GROWTH OF CULTURED CELLS USING CO-TRANSCRIPTION OF A Bcl2 ENCODING NUCLEIC ACID
05/15/2003WO2003040370A1 Weed controller metabolism proteins, genes thereof and use of the same
05/15/2003WO2003040345A2 Type 2 cytokine receptor and nucleic acids encoding same
05/15/2003WO2003040342A2 Method for generation of modular polynucleotides using solid supports
05/15/2003WO2003040341A2 Anti-hepatitis a virus antibodies
05/15/2003WO2003040340A2 Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
05/15/2003WO2003040329A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/15/2003WO2003040316A2 Selective elimination of cd52+ cells and uses thereof
05/15/2003WO2003040309A2 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
05/15/2003WO2003040307A2 Heteromultimeric tnf ligand family members
05/15/2003WO2003040188A1 Antibody stimulating il-1ra production
05/15/2003WO2003040187A1 Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof
05/15/2003WO2003040186A1 Monoclonal antibody against canine distemper virus and method of diagnosis of distemper
05/15/2003WO2003040185A2 Anti-n-glycolyl-neuraminic acid antibodies and their use for identifying glycoproteins
05/15/2003WO2003040183A2 Compounds for the diagnosis/prevention/treatment of alzheimer's disease
05/15/2003WO2003040170A2 Antibodies to cd40
05/15/2003WO2003040169A2 Human monoclonal antibodies to dendritic cells
05/15/2003WO2003040164A2 Antigen arrays presenting il-5, il-3 or eotaxin for treatment of allergic eosinophilic diseases
05/15/2003WO2003039587A1 Pharmaceutical composition comprising factor vii polypeptides and protein s inhibitors
05/15/2003WO2003039491A2 Novel isoforms of vascular endothelial cell growth inhibitor
05/15/2003WO2003039486A2 Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
05/15/2003WO2003039485A2 Stable liquid pharmaceutical formulation of igg antibodies
05/15/2003WO2003039471A2 Catalytic antibodies raised against sarin and process for the preparation thereof
05/15/2003WO2003039467A2 Monoclonal antibodies specific for beta-amyloid.
05/15/2003WO2003039462A2 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
05/15/2003WO2003039459A2 Viral vector production methods and compositions
05/15/2003WO2003039346A2 Diagnostics and therapeutics for ocular abnormalities
05/15/2003WO2003039327A2 Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof
05/15/2003WO2003039225A2 Antigen arrays comprising rankl for treatment of bone disease
05/15/2003WO2002097032A3 Proteins associated with cell growth, differentiation, and death
05/15/2003WO2002090508A3 Cell adhesion-mediating proteins and polynucleotides encoding them
05/15/2003WO2002086508A3 Elisa kit for the determination of cyp2c19 metabolic phenotypes and uses thereof
05/15/2003WO2002064795A3 Putative human enzymes
05/15/2003WO2002048366A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/15/2003WO2002048365A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/15/2003WO2002041842A3 Antibody pti-hs7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease
05/15/2003WO2002040654A3 A human serpin secreted from lymphoid cells lsi-01
05/15/2003WO2002030462A9 Hedgehog antagonists, methods and uses related thereto
1 ... 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 ... 1494